000950 重藥控股
按盤價 
5.250 +0.050 (+0.962%)
5.250 +0.050 (+0.962%) | 2026/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2025/12 人民幣(K¥) | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | ||
| 營業總收入 | 40,131,617 | -2.57% | 82,447,409 | 80,561,532 | 78,397,354 | 67,829,010 | |
| 減：營業總成本 | 39,510,768 | -2.24% | 81,307,115 | 79,839,412 | 77,352,038 | 66,608,402 | |
| 其中:營業成本 | 37,406,249 | -2.02% | 76,507,073 | 74,572,958 | 72,130,851 | 62,008,780 | |
| 財務費用 | 323,158 | -14.88% | 738,082 | 1,084,281 | 1,302,028 | 1,094,235 | |
| 資產減值損失 | (5,224) | 74.59% | (123,168) | (89,975) | (27,756) | (39,943) | |
| 公允價值變動收益 | (44) | -94.93% | (3,068) | 6,919 | 16,162 | 2,318 | |
| 投資收益 | 138,530 | 138.02% | 415,481 | 402,412 | 301,548 | 293,349 | |
| 其中：對聯營企業和合營企業的投資收益 | 160,206 | 1.15% | 479,395 | 396,688 | 291,454 | 286,195 | |
| 營業利潤 | 408,810 | -13.28% | 682,871 | 562,641 | 964,883 | 1,435,011 | |
| 利潤總額 | 418,130 | -10.51% | 671,860 | 557,508 | 966,329 | 1,472,490 | |
| 減：所得稅費用 | 105,600 | 34.94% | 150,531 | 155,717 | 236,042 | 309,496 | |
| 淨利潤 | 312,530 | -19.66% | 521,328 | 401,791 | 730,288 | 1,162,995 | |
| 減：非控股權益 | 58,079 | -45.58% | 134,613 | 118,798 | 105,654 | 210,719 | |
| 股東淨利潤 | 254,452 | -9.85% | 386,715 | 282,994 | 624,633 | 952,276 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.150 | -6.25% | 0.220 | 0.160 | 0.360 | 0.550 | |
| 每股派息 (元) * | -- | -- | 0.060 | 0.060 | 0.050 | 0.060 | |
| 每股淨資產 (元) * | 6.793 | 1.82% | 6.675 | 6.554 | 6.507 | 6.110 | |
| 審計意見 # | -- | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 報價延遲最少15分鐘，資料更新時間為 30/09/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
